Efficacy of breast cancer screening by age. New results swedish two‐county trial

Background. Several studies have found a smaller effect of breast cancer screening on breast cancer mortality in women aged younger than 50 years compared with older women. Various possible reasons have been suggested for this, but none firmly is established.

[1]  S. Wall,et al.  Breast cancer screening with mammography: overview of Swedish randomised trials , 1993, The Lancet.

[2]  L. Tabár,et al.  REDUCTION IN MORTALITY FROM BREAST CANCER AFTER MASS SCREENING WITH MAMMOGRAPHY Randomised Trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare , 1985, The Lancet.

[3]  L. Tabár,et al.  What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. , 1987, British Journal of Cancer.

[4]  S D Walter,et al.  Estimation of the duration of a pre-clinical disease state using screening data. , 1983, American journal of epidemiology.

[5]  G. Murphy,et al.  UICC meeting on breast‐cancer screening in pre‐menopausal women in developed countries. Geneva, 29 September‐1 October 1993 , 2007, International journal of cancer.

[6]  L. Tabár,et al.  Mammographic parenchymal patterns. Risk indicator for breast cancer? , 1982, JAMA.

[7]  L. Tabár,et al.  Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. , 1995, Statistics in medicine.

[8]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[9]  L. Garfinkel,et al.  Insights into breast cancer screening of younger women. Evidence from the 14‐year follow‐up of the breast cancer detection demonstration project , 1993, Cancer.

[10]  S. Shapiro,et al.  Periodic breast cancer screening in reducing mortality from breast cancer. , 1971, JAMA.

[11]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.

[12]  I. Henderson.  Biologic variations of tumors , 1992 .

[13]  N. Breslow.  Extra‐Poisson Variation in Log‐Linear Models , 1984 .

[14]  S. Duffy,et al.  Modelling the analysis of breast cancer screening programmes: sensitivity, lead time and predictive value in the Florence District Programme (1975-1986). , 1991, International journal of epidemiology.

[15]  L. Tabár,et al.  Update of the Swedish two-county program of mammographic screening for breast cancer. , 1992, Radiologic clinics of North America.

[16]  Norman E. Breslow,et al.  Statistical Methods in Cancer Research, Vol. II: The Design and Analysis of Cohort Studies. , 1990 .

[17]  I Persson,et al.  The relation between survival and age at diagnosis in breast cancer. , 1986, The New England journal of medicine.

[18]  A. Miller,et al.  Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[19]  L. Tabár,et al.  Breast screening, prognostic factors and survival--results from the Swedish two county study. , 1991, British Journal of Cancer.

[20]  L. Tabár,et al.  New swedish breast cancer detection results for women aged 40–49 , 1993, Cancer.

[21]  M. Moskowitz.  Guidelines for screening for breast cancer. Is a revision in order? , 1992, Radiologic clinics of North America.

[22]  F. Levi,et al.  Cancer incidence in five continents, vol. VI , 1993 .

[23]  M Moskowitz,et al.  Effects of lead time, length bias, and false‐negative assurance on screening for breast cancer , 1993, Cancer.

[24]  M S Fox,et al.  On the diagnosis and treatment of breast cancer. , 1979, JAMA.

[25]  Norman E. Breslow,et al.  The design and analysis of cohort studies , 1987 .

[26]  N E Day,et al.  Estimating the sensitivity of a screening test. , 1985, Journal of epidemiology and community health.